Cognition Therapeutics

CGTX Part 3 : The Investor's Dilemma - Partnership, Dilution, or Bust?

With a clear regulatory path and a drug demonstrating broad potential, Cognition Therapeutics has the scientific assets. Now, it all comes down to the money. The company's future hinges on securing a strategic partnership, presenting investors with a classic high-risk, high-reward scenario.